1. Home
  2. SCLXW vs YDESW Comparison

SCLXW vs YDESW Comparison

Compare SCLXW & YDESW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Scilex Holding Company

SCLXW

Scilex Holding Company

HOLD

Current Price

$0.20

Market Cap

0.0

Sector

Health Care

ML Signal

HOLD

YDESW

YD Bio Limited Warrants

N/A

Current Price

$0.49

Market Cap

0.0

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
SCLXW
YDESW
Founded
N/A
N/A
Country
United States
United States
Employees
30
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
N/A
N/A
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
SCLXW
YDESW
Price
$0.20
$0.49
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
8.2K
8.9K
Earning Date
03-07-2025
N/A
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$55,152,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
22.02
N/A
52 Week Low
$0.04
$0.36
52 Week High
$0.64
$2.85

Technical Indicators

Market Signals
Indicator
SCLXW
YDESW
Relative Strength Index (RSI) 60.28 46.88
Support Level $0.09 $0.45
Resistance Level $0.30 $0.76
Average True Range (ATR) 0.02 0.04
MACD 0.01 0.01
Stochastic Oscillator 84.39 65.72

Price Performance

Historical Comparison
SCLXW
YDESW

About SCLXW Scilex Holding Company

Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.

About YDESW YD Bio Limited Warrants

YD Bio Ltd is a biopharmaceutical company focusing on blood-based cancer detection, the development of stem cell- and exosome-based therapeutics with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need and serving as a trusted supplier of clinical testing drugs for pharmaceutical companies. Stem cell therapy uses versatile cells to repair or regenerate damaged tissues, offering innovative treatments for injuries, degenerative diseases, and immune disorders with potential for personalized medicine and tissue engineering.

Share on Social Networks: